gemfibrozil has been researched along with gemfibrozil 1-o-acylglucuronide in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Dalvie, D; Fu, Y; Khojasteh, SC; Ma, Y; Zhang, D | 1 |
| Fairchild, BA; Sallustio, BC | 1 |
| Evans, AM; Fairchild, BA; Nation, RL; Sallustio, BC; Shanahan, K | 1 |
| Fairchild, BA; Pannall, PR; Sallustio, BC | 1 |
| Evans, AM; Nation, RL; Sabordo, L; Sallustio, BC | 2 |
| Charman, WN; Prankerd, RJ; Scanlon, MJ; Shackleford, DM | 1 |
| Brogan, LR; Evans, AM; Lucas, AN; Milne, RW; Nation, RL; Shackleford, DM | 1 |
| Gipson, AE; Holsapple, J; Li, W; Ogilvie, BW; Parkinson, A; Rodrigues, AD; Toren, P; Zhang, D | 1 |
| Backman, JT; Kalliokoski, A; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A | 1 |
| Allen, A; Baer, BR; DeLisle, RK | 1 |
| Backman, JT; Honkalammi, J; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A | 1 |
| Backman, JT; Karonen, T; Neuvonen, PJ | 1 |
| Backman, JT; Honkalammi, J; Neuvonen, PJ; Niemi, M | 1 |
| Backman, JT; Neuvonen, PJ; Niemi, M; Tornio, A | 1 |
| Dai, M; Lin, H; Lin, J; Liu, A; Luo, M; Xie, M; Yang, J | 1 |
3 review(s) available for gemfibrozil and gemfibrozil 1-o-acylglucuronide
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
Topics: Anions; Binding Sites; Cytochrome P-450 CYP2C8; Drug Interactions; Glucuronides; Humans; Ligands | 2017 |
Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
Topics: Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Glucuronates; Humans; Hypolipidemic Agents; Membrane Transport Proteins | 2017 |
5 trial(s) available for gemfibrozil and gemfibrozil 1-o-acylglucuronide
| Article | Year |
|---|---|
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Cytochrome P-450 CYP2C8; Drug Interactions; Female; Gemfibrozil; Glucuronates; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Piperidines | 2008 |
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Topics: Administration, Oral; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Genotype; Glucuronates; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Molecular Probes; Organic Anion Transporters; Phenotype; Piperidines; Young Adult | 2009 |
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C8; Drug Interactions; Female; Gemfibrozil; Glucuronates; Humans; Indoles; Male; Phenylcarbamates; Sulfonamides; Tosyl Compounds; Young Adult | 2011 |
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Female; Gemfibrozil; Glucuronates; Humans; Hypoglycemic Agents; Male; Piperidines; Time Factors | 2011 |
Species-related exposure of phase II metabolite gemfibrozil 1-O-β-glucuronide between human and mice: A net induction of mouse P450 activity was revealed.
Topics: Adult; Animals; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme System; Drug Interactions; Gemfibrozil; Glucuronates; Humans; Hypolipidemic Agents; Liver; Male; Mice; Species Specificity; Time Factors; Young Adult | 2017 |
9 other study(ies) available for gemfibrozil and gemfibrozil 1-o-acylglucuronide
| Article | Year |
|---|---|
Biosynthesis, characterisation and direct high-performance liquid chromatographic analysis of gemfibrozil 1-O-beta-acylglucuronide.
Topics: Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Stability; Gemfibrozil; Glucuronates; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Mass Spectrometry; Quality Control | 1995 |
Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver.
Topics: Animals; Bile; Gemfibrozil; Glucuronates; Hypolipidemic Agents; In Vitro Techniques; Kinetics; Liver; Male; Perfusion; Rats; Rats, Sprague-Dawley | 1996 |
Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide.
Topics: Diazepam; Gemfibrozil; Glucuronates; Half-Life; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Male; Oxyphenbutazone; Pilot Projects; Protein Binding; Serum Albumin; Time Factors | 1997 |
Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation.
Topics: Animals; Biological Transport; Cell Membrane; Female; Gemfibrozil; Glucuronates; Hypolipidemic Agents; Liver; Male; Perfusion; Protein Binding; Rats; Rats, Sprague-Dawley; Sulfobromophthalein | 1999 |
Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide.
Topics: Acetaminophen; Animals; Biological Transport; Clofibric Acid; Gemfibrozil; Glucuronates; Liver; Male; Perfusion; Rats; Rats, Sprague-Dawley | 2000 |
Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.
Topics: Calorimetry; Chemistry, Pharmaceutical; Drug Compounding; Gemfibrozil; Glucuronates; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Micelles; Pharmaceutical Solutions; Surface Tension; Water | 2003 |
The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically generated gemfibrozil 1-O-acyl glucuronide in the isolated perfused rat liver.
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Genistein; Glucuronates; Kinetics; Liver; Male; Organ Culture Techniques; Rats; Rats, Sprague-Dawley | 2003 |
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Topics: Alamethicin; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Drug Interactions; Gemfibrozil; Glucuronates; Glucuronides; Humans; Hypolipidemic Agents; Mass Spectrometry; Microsomes, Liver; Uridine Diphosphate Glucuronic Acid | 2006 |
Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.
Topics: Alkylation; Aryl Hydrocarbon Hydroxylases; Catalytic Domain; Chromatography, High Pressure Liquid; Computer Simulation; Cytochrome P-450 CYP2C8; Gemfibrozil; Glucuronates; Heme; Humans; Hypolipidemic Agents; Mass Spectrometry; Oxidation-Reduction; Recombinant Proteins | 2009 |